Niraparib Maintenance Combinations in Advanced Pancreatic Cancer: Phase 1b/2 Results
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On July 7, 2022, Kim A. Reiss and colleagues from the Abramson Cancer Center published the results of a Phase 1b/2 clinical trial in The Lancet Oncology. The study evaluated two different maintenance strategies using the PARP inhibitor Niraparib in patients with advanced pancreatic cancer whose disease had not progressed after at least 16 weeks of platinum-based chemotherapy.
Study Design
The trial randomized 91 patients in a 1:1 ratio to receive:
- Niraparib + Nivolumab (Opdivo): Niraparib (200 mg daily) + Nivolumab (480 mg every 4 weeks).
- Niraparib + Ipilimumab (Yervoy): Niraparib (200 mg daily) + Ipilimumab (3 mg/kg every 3 weeks).
The primary endpoint was the 6-month progression-free survival (PFS) rate.
Key Efficacy Results (Median Follow-up 23 Months)
- 6-Month PFS Rate:
- Niraparib + Ipilimumab Group: 59.6%
- Niraparib + Nivolumab Group: 20.6%
- The combination of Niraparib and Ipilimumab showed a significantly higher likelihood of maintaining disease control at 6 months compared to the Nivolumab combination.
Safety Profile
Grade 3 or higher adverse events occurred in 51% of patients in the Niraparib + Ipilimumab group and 22% in the Niraparib + Nivolumab group.
- Nivo Combination Side Effects: Hypertension (8%), anemia (4%), and thrombocytopenia (4%).
- Ipi Combination Side Effects: Fatigue (14%), anemia (11%), and hypertension (9%).
Conclusion
The researchers concluded that for patients with advanced pancreatic cancer responding to platinum-based chemotherapy, maintenance therapy with Niraparib plus Ipilimumab significantly improved the 6-month PFS rate. In contrast, the combination with Nivolumab was less effective in this setting. These results suggest that the choice of immunotherapy partner for PARP inhibitors is critical in pancreatic cancer maintenance.
Source: The Lancet Oncology - Niraparib Maintenance Combinations
#PancreaticCancer #Niraparib #Nivolumab #Ipilimumab #PARPInhibitor #MaintenanceTherapy #CancerResearch
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4